RenovoRx Stock (NASDAQ:RNXT)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$0.80

52W Range

$0.70 - $1.45

50D Avg

$0.95

200D Avg

$1.09

Market Cap

$29.61M

Avg Vol (3M)

$258.55K

Beta

1.33

Div Yield

-

RNXT Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Aug 26, 2021

Website

RNXT Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24
Other Operating Segment	$43.00K

Fiscal year ends in Dec 24 | Currency in USD

RNXT Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$43.00K	-	-
Operating Income	$-10.97M	$-11.40M	$-9.95M
Net Income	$-8.81M	$-10.23M	$-9.77M
EBITDA	$-10.97M	$-11.39M	$-9.94M
Basic EPS	$-0.04	$-0.99	$-1.08
Diluted EPS	$-0.04	$-0.99	$-1.08

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 13, 25 | 4:30 PM

Q2 25Aug 14, 25 | 4:30 PM

Q1 25May 15, 25 | 4:30 PM

Peer Comparison

Ticker	Company
TVRD	Tvardi Therapeutics, Inc.
ANVS	Annovis Bio, Inc.
CELU	Celularity Inc.
ELUT	Elutia Inc.
CALC	CalciMedica, Inc.
BCAB	BioAtla, Inc.
RVPH	Reviva Pharmaceuticals Holdings, Inc.
LTRN	Lantern Pharma Inc.
PYPD	PolyPid Ltd.